Document Type
Article
Publication Date
2017
Status
Accepted
Abstract
People are angry about drug prices. What role, if any, should the FDA play in addressing this issue? Historically, the FDA’s answer has been “not our problem.” As the quality and safety agency, the FDA has repeatedly refused to get involved in drug pricing matters, even when its actions (and inactions) have contributed to the problem. We examine the circumstances under which the FDA should pay attention to pharmaceutical prices, and discuss the implications of it doing so.
GW Paper Series
GWU Law School Public Law Research Paper No. 2017-37; GWU Legal Studies Research Paper No. 2017-37
SSRN Link
https://ssrn.com/abstract=2970683
Recommended Citation
Hyman, David A. and Kovacic, William E., Risky Business: Should the FDA Pay Attention to Pharmaceutical Prices? (May 18, 2017). GWU Law School Public Law Research Paper No. 2017-37; GWU Legal Studies Research Paper No. 2017-37. Available at SSRN: https://ssrn.com/abstract=2970683